4 Receptors for gut regulatory peptides

Bailliere's Clinical Endocrinology and Metabolism

Volumn 8, Issue 1, 1994, Pages 77-110

  Laburthe, Marc ^a   Couvineau, Alain ^a   Amiranoff, Brigitte ^a   Voisin, Thierry ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BOMBESIN RECEPTOR; CHOLECYSTOKININ RECEPTOR; CYCLIC AMP; GALANIN; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN RECEPTOR; GASTRIN RELEASING PEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE; GLUCAGON RECEPTOR; HORMONE RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; NEUROKININ 2 RECEPTOR; NEUROKININ B; NEUROPEPTIDE Y RECEPTOR; NEUROTENSIN RECEPTOR; OPIATE; OPIATE RECEPTOR; PANCREAS POLYPEPTIDE; PEPTIDE HORMONE; PEPTIDE YY; PHOSPHATIDYLINOSITOL; SECRETIN; SOMATOSTATIN RECEPTOR; SUBSTANCE P RECEPTOR; TACHYKININ RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

CLONING; HUMAN; MOUSE; NONHUMAN; RAT; REVIEW; SIGNAL TRANSDUCTION;

ANIMAL; CYCLIC AMP; GALANIN; HUMAN; PEPTIDE YY; PEPTIDES; PHOSPHATIDYLINOSITOLS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0028044839     PISSN: 0950351X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-351X(05)80227-7     Document Type: Article

References (232)

1. Human distribution and release of a putative new gut hormone, peptide YY
2. Release of peptide YY (PYY) after resection of small bowel, colon or pancreas in man
3. ++ concentration
4. Stimulation of inositol phosphate production by neurotensin in neuroblastoma N1E115 cells: implication of GTP-binding proteins and relationship with the cyclic GMP response
5. Characterization of a vasoactive intestinal peptide (VIP)-sensitive adenylate cyclase in rat intestinal epithelial cell membranes
6. Characterization of specific binding sites for vasoactive intestinal peptide (VIP) in rat intestinal epithelial cell membranes
7. Functional GIP receptors in a hamster pancreatic beta cell line, In 111: specific binding and biological effects
8. Interaction of gastric inhibitory polypeptide (GIP) with the insulin-secreting pancreatic cell line In 111: characteristics of GIP binding sites
9. Gastric inhibitory polypeptide receptor in hamster pancreatic beta cells. Direct cross-linking, solubilization and characterization as a glycoprotein
10. Galanin receptors in a hamster pancreatic beta cell tumor: identification and molecular characterization
11. Mechanism of galanin-inhibited insulin release: occurrence of a pertussis toxin-sensitive inhibition of adenylate cyclase
12. Galanin receptors in the rat pancreatic beta cell line Rin m5F: molecular characterization by chemical cross-linking
13. Structural requirement for galanin action in the pancreatic beta cell line Rin m5F
14. A clonal rat pancreatic delta cell line (Rin 14B) expresses a high number of galanin receptors negatively coupled to a pertussis toxin-sensitive cAMP production pathway
15. Primary culture of PYY cells from canine colon
16. Neuropeptide Y (18–36) is a competitive antagonist of neuropeptide Y in rat cardiac ventricular membranes
17. M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord
18. Interaction of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with liver and fat cell plasma membranes: binding to specific sites and stimulation of adenylate cyclase
19. Porcine peptide having N-terminal histidine and C-terminal isoleucine amide: VIP-like and secretin-like effects in different tissues from rat
20. Glucagon and related peptides. Molecular structure and biological specificity
21. Molecular cloning of the bombesin/gastrin-releasing peptide receptor from Swiss 3T3 cells
22. Inhibitory effect of galanin on postprandial gastrointestinal motility and gut hormone release in humans
23. Inositoltriphosphate and diacylglycerol: two interacting second messengers
24. Receptor-effector coupling by G proteins
25. VASOACTIVE INTESTINAL PEPTIDE AND WATERY-DIARRHŒA SYNDROME
26. Neurotensin stimulates inositol trisphosphate-mediated calcium mobilization but not protein kinase C activation in HT 29 cells. Involvement of a G protein
27. Characterization of vasoactive intestinal peptide (VIP) receptors in human colonic epithelial cells
28. Solubilization and hydrodynamic characterization of guanine nucleotide-sensitive vasoactive intestinal peptide-receptor complexes from rat intestine
29. Identification and functional studies of a specific peptide YY-preferring receptor in dog adipocytes
30. Solubilization and molecular characterization of active galanin receptors from rat brain
31. Purification of a galanin receptor from porcine brain
32. Opioid-coupled second messenger systems
33. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from guinea pig. Binding of the radio-iodinated peptide
34. Vasoactive intestinal peptide receptors in pancreas and liver
35. Two distinct bombesin receptor subtypes are expressed and functional in human lung carcinoma cells
36. Structure and neurochemical organization of the enteric nervous system
37. The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium
38. The rat liver vasoactive intestinal peptide (VIP) binding site: molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor
39. Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences
40. The GIP receptor on pancreatic beta cell tumor: covalent cross-linking and molecular characterization
41. Molecular identification and structural requirement of vasoactive intestinal peptide (VIP) receptors in the human colon adenocarcinoma cell line HT-29
42. Solubilization of the liver vasoactive intestinal peptide receptor. Hydrodynamic characterization and evidence for an association with a functional GTP regulatory protein
43. Purification of VIP receptor from porcine liver by a newly designed one-step affinity chromatography
44. Functional and immunological evidence for stable association of solubilized VIP receptor and Gs protein from rat liver
45. The effect of neuropeptide Y and peptide YY on electrogenic ion transport in rat intestinal epithelia
46. The interaction of vasoactive intestinal polypeptide and secretin with liver cell membranes
47. Characterization of vasoactive intestinal peptide (VIP) receptors in mammalian lung
48. Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
49. + channels in insulin secreting cells via a pertussis toxin-sensitive G protein
50. Galanin: a novel pancreatic neuropeptide
51. Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3′,5′: monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig
52. The vasoactive intestinal peptide receptor on intact colonic adenocarcinoma cells (HT29-D4). Evidence for its glycoprotein nature
53. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells
54. Structural requirements for glucagon receptor binding and activation of adenylate cyclase in liver: study of chemically modified forms of the hormone, including N-alpha trinitrophenyl glucagon, an antagonist
55. Presence of VIP receptors in a human pancreatic adenocarcinoma cell line, modulation of the cAMP response during cell proliferation
56. Cloning of a delta opioid receptor by functional expression
57. 2+ channels in sensory neurons
58. Glycosylation of VIP receptors: a molecular basis for receptor heterogeneity
59. Galanin receptor and its ligands in the rat hippocampus
60. Non-peptide ligands for peptide receptors
61. Galanin: structural requirement for binding and signal transduction in Rin m5F insulinoma cells
62. 2 receptor
63. Receptors for gastrointestinal hormones
64. Signal transduction by cell surface receptors
65. Evidence for a cyclic AMP system highly sensitive to secretin in gastric glands isolated from rat fundus and antrum
66. Gastric inhibitory peptide (GIP), pancreatic glucagon and vasoactive intestinal peptide (VIP) are cAMP-inducing hormones in the human gastric cancer cell line HGT-1. Homologous desensitization of VIP receptor activity
67. Characterization of specific pancreatic polypeptide receptors on basolateral membranes of the canine small intestine
68. G proteins and regulation of adenylyl cyclase
69. Solubilization and characterization of active neuropeptide Y receptors from rabbit kidney
70. Interaction of glucagon-like peptide-1(7–36)amide and somatostatin-14 in RINm5F cells and in the perfused rat pancreas
71. Plasma enteroglucagon, peptide YY and gastrin in rats deprived of luminal nutrition, and after urogastrone-EGF administration: a proliferative role for PYY in the intestinal epithelium?
72. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy
73. Molecular cloning of substance P receptor cDNA from guinea-pig uterus
74. Evidence for regulation of peptide YY release by proximal gut
75. Effects of peptide YY on the growth of the pancreas and intestine
76. Solubilization of active and stable receptors for vasoactive intestinal peptide from rat liver
77. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor
78. Reduced peptide bond pseudopeptide analogues of secretin. A new class of secretin receptor antagonists
79. The hepatic glucagon receptor
80. Cloned human neuropeptide Y receptor couples to two different second messenger systems
81. Receptor solubilization, characterization and isolation
82. 2+ current in the RINm5f cell line
83. Promotion of differentiation in human colon carcinoma cells by vasoactive intestinal polypeptide
84. Cholecystokinin octapeptide-like immunoreactivity: histochemical localization in rat brain.
85. Vasoactive intestinal peptide binding to specific receptors on rat parotid acinar cells induces amylase secretion accompanied by intracellular accumulation of cyclic adenosine 3′-5′ monophosphate
86. Characterization of peptide YY receptors in the brain
87. Characterization of the receptor for peptide YY and avian polypeptide in chicken and pig brain
88. Molecular cloning and expression of a cDNA encoding the secretin receptor
89. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide
90. Progress in the development of potent bombesin receptor antagonists
91. Interaction of CCK with pancreatic acinar cells
92. Identification of the glucagon receptor in rat liver membranes by photoaffinity crosslinking
93. Molecular cloning of five GTP-binding protein cDNA species from rat olfactory neuroepithelium
94. Molecular weight determination by radiation inactivation
95. Membrane receptors for hormones and neurotransmitters
96. Tissue-specific expression of the rat galanin gene
97. Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G protein
98. Vasoactive intestinal peptide
99. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization.
100. Isolation and characterization of a new pancreatic polypeptide hormone
101. Autoradiographic localization of binding sites for galanin and VIP in small intestine
102. Pharmacology and biochemistry of neurotensin receptors
103. Expression cloning of a rat brain somatostatin receptor cDNA
104. Expression cloning and characterization of the canine parietal cell gastrin receptor
105. Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor
106. Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure
107. Peptide YY and neuropeptide Y in the gut: availability, biological actions and receptors
108. Peptide receptors in intestinal epithelium
109. Molecular analysis of vasoactive intestinal peptide receptors. A comparison with receptors for VIP-related peptides
110. VIPergic control of intestinal epithelium in health and disease
111. Vasoactive intestinal peptide (VIP): a potent stimulator of adenosine 3′5′: cyclic monophosphate accumulation in gut carcinoma cell lines in culture
112. The expression of cell surface receptors for VIP, secretin and glucagon in normal and malignant cells of the digestive tract
113. Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat
114. Vasoactive intestinal peptide (VIP) control of cyclic AMP levels in seven human colorectal adenocarcinoma cell lines in culture
115. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin
116. Molecular identification of VIP receptors in rat intestinal epithelium by covalent cross-linking: evidence for two classes of binding sites with different structural and functional properties
117. Interaction of PHM, PHI and 24-glutamine PHI with human VIP receptors from colonic epithelium: comparison with rat intestinal receptors
118. 1 hGRF is a competitive VIP antagonist in the rat
119. Interaction of peptide YY with rat intestinal epithelial plasma membranes: binding of the radioiodinated peptide
120. Development of vasoactive intestinal peptide-responsive adenylate cyclase during enterocytic differentiation of Caco-2 cells in culture. Evidence for an increased receptor level
121. Functional VIP receptors in the human mucus-secreting colonic epithelial cell line CL.16E.
122. Gut peptide receptors and signal transduction in intestinal epithelium: state of the art
123. Peptide receptors and signal transduction in the digestive tract
124. Characterization of galanin receptors in the insulin secreting cell line Rin m5F: evidence for coupling with an inhibitory GTP-regulatory protein (Gi)
125. Structural requirement for galanin interaction with receptors from pancreatic beta cells and from brain tissue of the rat
126. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 subtype
127. Methods used for the study of opioid receptors
128. The somatostatin receptor in the GI tract
129. Cloning, functional expression and developmental regulation of a neuropeptide Y receptor from Drosophila melanogaster
130. Selective amplification and cloning of four new members of the G protein-coupled receptor family
131. Neuroendocrine potential of the colon and rectum.
132. Cloning and sequencing of porcine LH-hCG receptor cDNA: variants lacking transmembrane domain
133. A historical overview of the gastroenteropancreatic regulatory peptides
134. Gastroenteropancreatic regulatory peptide structures: an overview
135. Galanin inhibits insulin secretion and induces hyperglycaemia in dogs
136. Lutropin-choriogonadotropin receptor: an unusual member of the G protein-coupled receptor family
137. Recent insights in phosphatidylinositol signalling
138. 2+ through breakdown of phosphoinositides to induce catecholamine secretion. Role of IP3 in exocytosis
139. Photoaffinity labelling of the vasoactive intestinal peptide binding site on intact human colonic adenocarcinoma cell line (HT29-D4). Synthesis and use of photosensitive vasoactive intestinal peptide derivatives
140. Synthesis and biological activity of new peptide segments of gastrin exhibiting gastrin antagonist property
141. cDNA cloning of bovine substance-K receptor through oocyte expression system
142. Solubilization of receptor for pituitary adenylate cyclase activating polypeptide from bovine brain
143. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
144. Receptors for neuropeptide Y: multiple subtypes and multiple second messengers
145. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells
146. Two brain cholecystokinin receptors: implications for behavioral actions
147. Covalent cross-linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cell in culture (HT-29)
148. Vasoactive intestinal polypeptide and related peptides. Isolation and chemistry
149. Doubt expressed about identity of remaining orphan clone. RDC1 may not be VIP receptor
150. Vasoactive intestinal peptide receptor on liver plasma membranes: characterization as a glycoprotein
151. Neuropeptide Y: differential binding to rat intestinal laterobasal membranes
152. High affinity binding proteins for pancreatic polypeptide on rat liver membranes
153. ++ concentration
154. Studies and perspectives of protein kinase C
155. The molecular heterogeneity of protein kinase C and its implications for cellular regulation
156. Molecular identification of receptor for pituitary adenylate cyclase activating polypeptide
157. Truncated glucagon-like peptide-1 (proglucagon 78–107 amide), an intestinal insulin-releasing peptide, has specific receptors on rat insulinoma cells (RIN 5AH)
158. Galanin: evidence for a hypothalamic site of action to release growth hormone
159. The hepatic glucagon receptor: a comparison study of regulatory and structural properties
160. 17)VIP
161. Peptide YY inhibits meal-stimulated pancreatic and gastric secretion.
162. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins
163. Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat
164. Multiple neurokinin receptors: recent developments
165. Actions of Gila monster venom on dispersed acini from guinea pig pancreas
166. Receptor for neuropeptides (neurokinins): functional studies
167. A somatostatin receptor negatively coupled to adenylate cyclase in the human gastric cell line HGT-1
168. Solubilization and immunopurification of a somatostatin receptor from the human gastric tumoral cell line HGT-1
169. Characterization of glucagon-like peptide-1(7–36)amide receptors of rat lung membranes by covalent cross-linking
170. Sequence and expression of a neuropeptide Y receptor cDNA
171. Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig: structural requirement for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3′:5′-monophosphate
172. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes
173. PACAP and VIP receptors in rat liver membranes
174. Characterization of vasoactive intestinal peptide receptors by a photoaffinity label. Site-specific modification of vasoactive intestinal peptide by derivatization of the receptor-bound peptide.
175. Characterization of a gastrin-type receptor on rabbit gastric parietal cells using L 365,260 and L 364,718
176. Galanin: a newly isolated biologically active neuropeptide
177. Construction of a porcine adrenal medullary cDNA library and nucleotide sequence analysis of two clones encoding a galanin precursor.
178. Laminar and regional distibution of galanin binding sites in cat and monkey visual cortex determined by in vitro receptor autoradiography
179. Galanin binding sites in rat gastric and jejunal smooth muscle membrane preparations
180. Vasoactive intestinal peptide (VIP) control of glycogenolysis in the human colon carcinoma cell line HT-29 in culture
181. 1 hGRF discriminates between VIP receptors from rat liver and intestinal epithelium
182. VIP receptors and control of short circuit current in the human intestinal clonal cell line C1.19A
183. Vasoactive intestinal peptide
184. Polypeptide with broad biological activity: isolation from small intestine
185. Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissues
186. Characterization of a common VIP-PACAP receptor in human small intestinal epithelium
187. Receptors on phaeochromocytoma cells for two members of the PP-fold family—NPY and PP
188. Identification and molecular characterization of galanin receptor sites in rat brain
189. Peptide YY and neuropeptide Y inhibit vasoactive intestinal peptide-stimulated cyclic AMP production in rat small intestine: structural requirement of peptides for interacting with peptide YY-preferring receptors
190. Galanin can inhibit insulin release by a mechanism other than membrane hyperpolarization or inhibition of adenylate cyclase
191. Preparation of enriched plasma membranes from bovine gallbladder muscularis for characterization of cholecystokinin receptors
192. Cloning and expression of a rat neuromedin K receptor cDNA
193. Diversity of G proteins in signal transduction
194. Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq
195. Gastrin receptors on isolated parietal cells
196. Introduction to receptors
197. Cloning and functional characterization of a complementary DNA encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor
198. Cloning and expression of the human vasoactive intestinal peptide receptor
199. Molecular characteristics and evidence for internalization of vasoactive intestinal peptide (VIP) receptors in the tumoral rat pancreatic acinar cell line AR 4-2 J
200. Mucosal gastrin receptor. IV. Binding specificity
201. The effects of bombesin on polyphosphoinositide and calcium metabolism in Swiss 3T3 cells
202. Structure and functional expression of the cloned rat neurotensin receptor
203. Neuropeptide Y. A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide
204. Galanin, a novel biologically active peptide from porcine intestine
205. Synthesis of receptor antagonists of neuropeptide Y
206. Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1
207. A fragment of vasoactive intestinal peptide, VIP (10–28), is an antagonist of VIP in the colon carcinoma cell line, HT-29
208. Galanin inhibits insulin secretion by direct interference with exocytosis
209. Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein
210. Cloning and expression of a novel mouse somatostatin receptor (SSTR2B)
211. Functional somatostatin receptors on a rat pancreatic acinar cell line.
212. Receptors for neuropeptides: receptor isolation studies and molecular biology
213. Distribution of the common peptide YY/neuropeptide Y receptor along rat intestinal villus-crypt axis
214. r 44000 glycoprotein
215. Peptide YY receptors in the proximal tubule PKSV-PCT cell line derived from transgenic mice. Relation with cell growth.
216. cDNA cloning, characterization, and brain region-specific expression of a neuromedin-B-preferring bombesin receptor
217. 2 as a vasoactive intestinal peptide (VIP) antagonist
218. Neuropeptide receptor subtypes, Y1 and Y2
219. Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas
220. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression
221. PCR and the cloning of receptor subtype genes
222. + channels that are blocked by hypoglycemia-inducing sulfonylureas in insulin-secreting cells are activated by galanin, a hyperglycemia-inducing hormone
223. Expression of the human neuropeptide tyrosine Y1 receptor
224. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney
225. Cloning of a novel somatostatin receptor, SSTR3, coupled to adenylylcyclase
226. Direct coupling of the somatostatin receptor to potassium channels by a G protein
227. Molecular characterization of a functional cDNA for rat substance P receptor
228. Characterization of gastrin receptors on guinea pig pancreatic acini.
229. Interaction of peptides related to VIP and secretin with guinea pig pancreatic acini.
230. Vasoactive intestinal polypeptide receptor binding sites in the human gastrointestinal tract: localization by autoradiography
231. The use of cultured cell lines in studies of intestinal cell differentiation and function